Clinical Trial Update: Post-authorization Safety Study of Iptacopan in Adult Patients With Paroxysmal Nocturnal Hemoglobinuria (PNH) Using Data From the IPIG PNH Registry

View source ↗

Summary

Post-authorization safety study evaluating iptacopan in adults with paroxysmal nocturnal hemoglobinuria using data from the IPIG PNH registry.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Paroxysmal Nocturnal Hemoglobinuria

Drugs mentioned

• iptacopan (iptacopan)

Snippet

Sponsor: Novartis Pharmaceuticals | Conditions: Hemoglobinuria, Paroxysmal | Status: ACTIVE_NOT_RECRUITING